Pulmonary vascular cell hyperproliferation is characteristic of pulmonary vascular remodeling in pulmonary arterial hypertension. A noninvasive imaging biomarker is needed to track the pathology and assess the response to novel treatments targeted at resolving the structural changes. Here, we evaluated the application of radioligand 3′-deoxy-3′-[18F]-fluorothymidine ( 18 FLT) using positron emission tomography.
FLT) using positron emission tomography.
METHODS AND RESULTS:
We performed dynamic 18 FLT positron emission tomography in 8 patients with idiopathic pulmonary arterial hypertension (IPAH) and applied in-depth kinetic analysis with a reversible 2-compartment 4k model. Our results show significantly increased lung 18 FLT phosphorylation (k 3 ) in patients with IPAH compared with nonpulmonary arterial hypertension controls (0.086±0.034 versus 0.054±0.009 min −1 ; P<0.05). There was heterogeneity in the lung 18 FLT signal both between patients with IPAH and within the lungs of each patient, compatible with histopathologic reports of lungs from patients with IPAH. Consistent with 18 FLT positron emission tomographic data, TK1 (thymidine kinase 1) expression was evident in the remodeled vessels in IPAH patient lung. In addition, hyperproliferative pulmonary vascular fibroblasts isolated from patients with IPAH exhibited upregulated expression of TK1 and the thymidine transporter, ENT1 (equilibrative nucleoside transporter 1). In the monocrotaline and SuHx (Sugen hypoxia) rat pulmonary arterial hypertension models, increased lung P ulmonary arterial hypertension (PAH) is characterized by structural remodeling of the pulmonary vasculature leading to increased pulmonary artery (PA) pressure and progressive right heart dysfunction. [1] [2] [3] Histopathology of lungs from patients with PAH at the end stage of their disease shows a complex pulmonary pathology, including aberrant proliferation of pulmonary vascular cells, inflammatory cell infiltration, and deposition of extracellular matrix. [4] [5] [6] The licensed treatments for PAH are based on restoration of an imbalance in vasoactive factors favoring vasoconstriction. Although these drugs improve symptoms, they fail to halt the disease and have a limited effect on survival. 7 Innovative treatment strategies that inhibit the excessive proliferation of lung vascular cells, for example, with the receptor tyrosine kinase inhibitor imatinib (IMA) 8 and the metabolic modulator dichloroacetate (DCA), 9 show great promise in the preclinical setting. 10 Interindividual variation in response to treatment is well recognized and was evident in the IMA (IMPRES) trial (Imatinib in Pulmonary Arterial Hypertension, a Randomized, Efficacy Study), as well as the recent DCA study. 11, 12 A possible explanation is heterogeneity in pulmonary vascular remodeling in PAH, with some patients exhibiting profound active vascular proliferation but others a more quiescent state of end-stage fixed pulmonary vascular pathology. A new tool for assessing PAH pathology in vivo would greatly improve the potential to translate therapeutic strategies targeted at resolving pulmonary vascular remodeling into the clinic. Ideally, such a tool would allow a strategy of precision medicine with therapies tailored to individual patients.
Positron emission tomography with appropriate ligands allows for spatial detection and localization of pathophysiological processes in vivo. Radioactive ligands, such as 18 F-flurodeoxyglucose ( 18 FDG) 13 and 3′-deoxy-3′-[18F]-fluorothymidine ( 18 FLT), 14, 15 have been used in oncology to stratify patients and assess disease progression and response to treatment and predict clinical outcomes. 18 FDG tracks general cellular glucose metabolism, which may correlate with proliferation in some tumors, but does not provide a direct measure of cell growth. 16 18 FLT is a marker for cell proliferation 14, 15 that correlates closely with histological markers, such as proliferating cell nuclear antigen, Ki-67 and S-phase fraction. 17-20 18 FLT is a fluorine-modified thymidine analogue that is transported into the cell via passive diffusion and by nucleoside transporters, such as the ENT1 (equilibrative nucleoside transporter 1), in a manner similar to thymidine. 21 Thereafter, 18 FLT is phosphorylated by TK1 (thymidine kinase 1) and trapped intracellularly at a rate proportional to TK1 activity, which is elevated during the S phase of the cell proliferation cycle but decreased or absent in quiescent cells. [22] [23] [24] [25] This tool has been used to accurately measure DNA synthesis in cell cultures using 3H-thymidine and supports the view that 18 FLT more accurately reports on proliferation. Importantly, 18 FLT PET is recognized for evaluating whole tumor proliferation heterogeneity. 26 Few studies have explored the application of PET imaging in PAH. Previously, we have described 18 FDG-PET as a tool for following response to treatment in animal models and the signal from patients with PAH, 9, 12 but it reports both proliferation and inflammation. Here, we evaluate the potential of 18 FLT PET as an imaging biomarker for assessing the distinctive hyperproliferative pulmonary vascular pathology seen in PAH. First, we examined 18 FLT lung uptake in patients with idiopathic PAH (IPAH) in comparison with control subjects. Second, we assessed whether 18 FLT PET could track pulmonary pathology in animal PAH models and the response to targeted therapies. Third, we examined ENT1 and TK1 expression in lung tissues and pulmonary vascular fibroblasts isolated from patients with IPAH to understand the determinants of lung 18 FLT uptake in PAH.
METHODS
The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.
Patient Population
Eight patients (Table 1) diagnosed with IPAH according to the European Respiratory Society guidelines 27 were recruited from
CLINICAL PERSPECTIVE
With the focus now on developing drugs that tackle pulmonary vascular remodeling (as opposed to vasoconstriction), we explored the use of dynamic 3′-deoxy-3′-[18F]-fluorothymidine ( 18 FLT) positron emission tomographic imaging with kinetic analysis in patients with idiopathic pulmonary arterial hypertension as a noninvasive tool to report on pulmonary vascular pathology. We show that patients with idiopathic pulmonary arterial hypertension demonstrate increased lung 18 FLT uptake, reflected in 18 FLT phosphorylation k3, with both inter-and intra-patient variability in the signal. Using animal models and cells from patients with idiopathic pulmonary arterial hypertension, we demonstrate that lung 18 FLT uptake reflects pulmonary vasculature cellular proliferation and responds to drugs that reduce pulmonary vascular remodeling. We suggest that 18 FLT positron emission tomography might be a useful tool for identifying patients who might benefit the most from antiremodeling therapy and so inform precision medicine.
the VU University Medical Center; both treatment-naive and treated patients were included in this study. We made use of 18 FLT PET data sets from an oncology study of non-small cell lung cancer patients 28 from the VU University Medical Center. Six subjects with 1-sided lung tumor were identified, and 18 FLT uptake from the tumor-free side of the lung was used as control. The study was approved by the Medical Ethical Review Committee of the VU University Medical Center (ToetsingOnline: NL49166.029.14), and all subjects gave informed consent.
Right Heart Catheterizations and Cardiac Magnetic Resonance Imaging
All patients underwent right heart catheterization and cardiac magnetic resonance imaging within 1 month of their PET/computed tomographic (CT) scan, and in this period, all patients were stable on pulmonary hypertension-targeted therapy. A balloon-tipped, flow-directed 7.5F triple-lumen Swan-Ganz catheter (Edwards Lifesciences LLC, Irvine, CA) was inserted in the PA via the jugular vein or femoral vein under local anesthesia and constant ECG monitoring, and measurements were performed according to the guidelines. 27 Catheter ports were placed in the right atrium, right ventricle (RV), and PA, and the zero reference level for the pressure transducer was placed at midthoracic level in supine position.
Cardiac magnetic resonance imaging scans were performed on a Siemens 1.5T Sonato or Avanto scanner (Siemens Medical Solutions, Erlangen, Germany). Acquisition and postprocessing were performed as described previously. 29 Summarized short-axis images of the right and left ventricle (LV) were analyzed using MASS software (MEDIS Medical Imaging Systems, Leiden, the Netherlands). Endocardial borders of the RV were manually traced on end-diastolic images and on end-systolic images. RV and LV end-diastolic and end-systolic volumes were assessed using the Simpson rule.
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Patients With IPAH 18 FLT PET 18 FLT was synthesized as described previously. 31 Minimum 4 hours of fasting was instructed before the PET scan; patients with IPAH were scanned on a Philips Ingenuity PET/CT (Philips Healthcare, Best, the Netherlands), whereas control data sets were from a Philips Gemini TF-64 PET/CT (Philips Healthcare, Best, the Netherlands) using an identical scanning protocol. First, after a scout CT scan, patients with IPAH were positioned with lungs centered in the field of view of the PET scanner. Then, a dynamic 60-minute emission scan was started simultaneously with automated bolus intravenous injection of 370 MBq of 18 FLT (0.8 mL/s). After completion of the emission scan, a low-dose CT scan was performed to correct for photon attenuation and scatter. Finally, emission data were reconstructed in a 36 frame (1×10, 8×5, 4×10, 3×20, 5×30, 5×60, 4×150, 4×300 and 2×600 s) using the 3-dimensional (3D) row-action maximum likelihood algorithm, applying all appropriate corrections for dead time, decay, scatter, attenuation, and normalization. During the scan, venous blood samples were withdrawn at 5, 10, 20, 30, 40, and 60 minutes post-injection and measured for the presence of radiolabeled metabolites ( 18 F-glucuronide) and the ratio of plasma and whole-blood activity concentrations as described.
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Kinetic Model for Data Analysis
18
FLT PET data were analyzed using the plasma kinetic model as described previously. 31 The model consists of 3 or 4 rate constants, of which k 3 represents phosphorylation of 18 FLT by thymidine kinase, and this rate constant was assumed to the most closely represent proliferation rate, thus used to represent the lung 18 FLT uptake. The model can be described using
, in which C PET (t) represents the measured pulmonary activity concentrations; C T (t), the activity according to the plasma kinetic model; and C A (t) and C V (t) are arterial and venous blood concentrations, respectively. To correct for contamination of the signal by blood-pool activity, V A (arterial blood volume fraction) and V V (venous blood volume fraction) were added to the model. For C T (t), both an irreversible 2-compartment 3k model and a reversible 2-compartment 4k model (2T4k) were tested, and the best fit was obtained. The use of an irreversible or reversible 2-tissue model was evaluated using Akaike information criterion. 33 For all patients and controls, Akaike information criterion showed a significantly improved fit using a reversible 2T4k model ( Figure I in the Data Supplement), and consequently, all results below are obtained using this model. In this model, K 1 represents the rate constant for transport of 18 FLT from blood into tissue, k 2 represents the rate constant of transfer from tissue back to blood, k 3 reflects the rate constant of phosphorylation of 18 FLT, and k 4 describes the rate of dephosphorylation.
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Input Functions and Model Selection
The lung has a dual circulation with perfusion coming from both the pulmonary and systemic (bronchial) circulation; recent literature suggests that systemic perfusion may become more important in PAH, for example, increased from 1% to 18% to 30% (total systemic cardiac output to bronchial output).. [35] [36] [37] Definition of the appropriate model and input function was performed in 2 steps. First, for all controls, the input functions were obtained in the RV cavity, PA, or ascending aorta (AA). Spillover from the blood was included in all analyses, and an additional correction for spillover of activity from the second blood compartment (ie, bronchial or pulmonary) was performed by drawing a region of interest (ROI) in either the PA or left atrium. We tested the following combinations of input functions for the controls: RV with and without spillover from the left atrium or AA (RV, combination of input functions from the right ventricle and pulmonary artery, and combination of input functions from the right ventricle and left atrium), PA with and without spillover from the left atrium or AA (PA or combination of input functions from the pulmonary artery and left atrium), and AA with and without spillover from the PA (AA, combination of input functions from the ascending aorta and left atrium, and combination of input functions from the ascending aorta and pulmonary artery). These combinations were tested for all possible compartmental modeling, including both the irreversible 2-compartment 3k model and for the 2T4k model. For control and patient data, adding spillover corrections for input function resulted in reduced Akaike information criterion, indicating a significantly improved fit. Based on Akaike information criterion, the reversible 2-tissue model was used for all PET data analysis. Optimal fits were obtained for combination of input functions from the pulmonary artery and left atrium in 50% of the lungs, combination of input functions from the ascending aorta and pulmonary artery in 20% and combination of input functions from the right ventricle and left atrium in 30%, showing that an input from the pulmonary circulation with pulmonary-venous spillover correction yielded optimal fits in a large majority of regions. Because we were looking for an input function model that could be applied to other tracers, we chose to discard the RV input function to avoid potential issues of spillover from the RV wall in tracers that show myocardial uptake.
After this initial analysis, the presence or absence of a dual circulation was tested by modifying the kinetic model, allowing for an input from both the arterial (obtained from the AA) and pulmonary (PA) circulation. When this method was applied to the data of our patients with PAH, K 1,bronchial was consistently <0.0001, whereas K 1,pulmonary was on average 0.056 mL×g −1 ×min −1 (range, 0.044-0.079). In addition, using 2 different input functions (PA/AA) yields virtually identical values with no significant differences between both measurements.
This indicated an absence of significant bronchial input or at least an inability to measure this input. These results led to the conclusion that a single input from the PA with spillover correction from the PA and the left atrium yielded optimal results and used as input function.
Because the best model fit was obtained using a pulmonary input function, this was used for further calculations. Five 1-cm diameter ROIs were drawn in the PA at the level of the pulmonary trunk on early frames showing the first pass of the bolus through the pulmonary circulation. Average activity through time C PA (t) was obtained from this region and assumed to represent the total supply of radioactivity to the lungs C A (t) in the Equation. To obtain the arterial input function C PL (t), C PA (t) was multiplied with a sigmoid function fitted through the ratio of plasma and whole-blood activity concentrations and a second sigmoid function fitted through the fraction of nonmetabolized tracer. This correction was performed as described previously. 31 A second set of ROIs was drawn in left atrial cavity in at least 3 slices. Average activity concentrations C LA (t) were obtained and used as correction factor for venous blood concentrations in the lungs C V (t) in the Equation.
Lung Segmentation
Pulmonary activity concentrations were obtained using the low-dose CT scan. Using automated region-growing methods, a region of low tissue density between 0.05 and 0.6 g/mL was obtained for each lung. A layer of 2 voxels (8 mm) was eroded from the borders of each lung region to reduce the effects of respiratory motion, spill-in of activity from the liver, and other partial volume effects. To avoid any effects of a gradient signal in the lungs and of differences in the field of view of the scanner and patient positioning, data from a 2-cm region at the level of the bifurcation of the PA were used for analysis using the ROIs drawn in the PA ( Figure II in the Data Supplement).
Parametric Mapping
To assess the spatial distribution of 18 FLT uptake within the lungs, volume of distribution was estimated from the slope of the linear regression on the Logan plot. 38 A parametric 3D map was generated by using volume of distribution values measured per voxel basis, typically 200 000 voxels (2 mm 2 per voxel) for a human subject.
Animals and Experimental Design
Adult Sprague-Dawley rats (body weight, 200-250 g; Charles River, United Kingdom) were used, littermates age-matched animals were assigned to study groups randomly. Only male rats were used to establish pulmonary hypertension models according to our previous experience. 9 All experiments were conducted in accordance with the UK Home Office Animals (Scientific Procedures) Act 1986 (London, United Kingdom).
Monocrotaline Model
Pulmonary hypertension was induced by subcutaneous injection of monocrotaline (MCT, 60 mg/kg; Sigma-Aldrich) in rat. In our experience, pulmonary arterial pressure is marginally elevated in rats 1 week after MCT injection 39 but significantly increased after 4 weeks. Histological examination of the MCT lung shows progressive vascular remodeling (proliferation) 1 and 4 weeks post-MCT injection. 9 Experimental design: (1)
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FLT PET-after MCT-induced PH progression; 18 FLT PET scans were performed in control and MCT PAH rats 1 week and 4 weeks after injection. (2) 18 FLT PET-to assess the effects of treatments in MCT PH model; both IMA and DCA have demonstrated efficacy in reducing pulmonary vascular proliferation of the MCT-induced PAH rat in our previous study. 9 Rats were divided into 4 groups (n=6 per group): (1) control, (2) MCT 4 weeks; (3) MCT rats treated with DCA 70 mg/kg per day in drinking water (DCA; Sigma-Aldrich, United Kingdom), and (4) MCT rats treated with IMA 100 mg/kg per day (LC Laboratories) by oral gavage. Each treatment was started 2 weeks post-MCT injection and continued for the following 2 weeks. At the end of the treatment, 18 FLT PET scans were performed, and tissues were collected for biochemical and histological examination.
SuHx Model
Pulmonary hypertension was induced by a single subcutaneous injection of SU5416 (25 mg/kg; Tocris Bioscience, Bristol, United Kingdom) followed by 4 weeks in normobaric hypoxic chamber (Fio 2 =10%, maintained by nitrogen supply). Control rats were injected with the vehicle alone and kept in normoxic condition. After 4 weeks of hypoxia exposure, all the SuHx (Sugen hypoxia) rats were returned to normoxia for an additional 6 weeks before performing 18 FLT PET imaging.
In Vivo
FLT PET in Rat
In vivo imaging was performed using a Siemens Inveon smallanimal multimodality PET/CT system (Siemens Healthcare Molecular Imaging) using a protocol described previously. 9 Briefly, rats were anaesthetized with isoflurane (2%-4%), and ventilation was adjusted to maintain Po 2 , Pco 2 , and pH within normal range. After the completion of the CT scan, 18 FLT (≈35 MBq, <0.5 mL) was injected through tail vein catheter. Dynamic emission scans were acquired in list-mode format for 60 minutes using conventional full-ring, whole-body PET. During PET scanning, serial blood samples were taken via a femoral artery line (20 µL each) 8 samples at 1 minute and then at 2, 3, 5, 10, 15, 30, 45, and 60 minutes. At the end, animals were euthanized, and tissue samples (lung, RV, kidney, and liver) were collected for γ-counting, as well as snap-frozen for biochemical measurement. The ratio of RV to LV plus the septum mass (RV/LV+septum) was used as an index of RV hypertrophy. Left lungs were inflated and fixed with 10% formalin for histology examination.
Data Analysis
After the PET scanning of each animal, the data were saved using an anonymous coding system in the Biological Imaging Center at the Imperial College. PET image data were sorted into 0.5 mm sinogram bins, and 33 time frames and images were reconstructed using filtered back projection with CT-based attenuation correction. The frame durations used for the study were 12×5, 4×15, 6×30, and 11×300 s. The reconstructed CT and PET images were analyzed using the 3D visualization toolbox in the Inveon Research Workplace software (Siemens Healthcare Molecular Imaging).
The whole-lung tissue time-activity curves were calculated from lung PET images coregistered with ROI on CT lung images, covering the lung volume with clearly visible boundaries adjusted by CT density thresholding. Cumulative images during 0 to 60 minutes were used for kinetic analysis of tracer uptake. The image-derived input functions were determined individually by sampled arterial plasma time-activity curves or the PET image-derived activity curve from the LV blood pool.
Decay corrected whole-lung time-activity curves were normalized for injected activity (kBq) and body weight to obtain standardized uptake value. The dynamic image data were fitted to a 2-compartment 4k model using the Matlab-based in-house kinetic analysis software package (CLICKFIT). In this model, k 1 represents the rate constant for the transport of 18 FLT from blood into tissue, k 2 represents the rate constant of the transport of 18 FLT from tissue to blood, k 3 reflects the rate constant of phosphorylation of 18 FLT, and k 4 describes the rate of 18 FLT dephosphorylation.
Biodistribution
The plasma and tissue samples (lung, RV, LV, septum, liver, and kidney) harvested after PET scanning were weighed and measured for radioactivity in a gamma counter. All data were corrected for radioactivity decay. The amount of radioactivity was expressed as percentage of injected dose per gram of tissue or blood.
Histology Examination
Rat transverse lung sections were processed for elastic Van Gieson and hematoxylin and eosin staining. Peripheral vessels <100 µm in lung were counted blindly under microscope (40×), and pulmonary vascular remodeling was expressed as the proportion of vessels with double elastic lamina to total vessels counted. Lung sections were also processed for Ki-67 (1:50; Thermo Scientific), CD68 (cluster of differentiation 68; 1:50; Serotec), TK1 (1:50; Abcam), and ENT1 (1:100; Abcam) immunostaining. Ki-67 score was calculated on a minimum of 20 randomly selected 40× high-power fields per slide, and Ki-67-positive cells around the vessels (<100 μm) were counted (≈40-50 vessels per slide). The number of Ki-67-positive cells per vessels was calculated for comparison between groups. CD68-positive cells were counted in wholelung tissue sections and expressed as per mm 
Western Blotting
Rat lung samples were homogenized in radio immunoprecipitation assay buffer (150 mmol/L sodium chloride, 1.0% NP-40 or Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 50 mmol/L Tris, pH 8.0, supplemented with protease inhibitor; Roche). Western blotting was performed according to the manufacturer's suggestions (rabbit polyclonal anti-TK1 and anti-ENT1, 1:1000; Abcam). Proteins were detected by Novex ECL chemiluminescence (Invitrogen). Optical densities of individual bands were measured, and protein expression was standardized with GAPDH.
Cell Culture
PA adventitial fibroblasts isolated from the lungs of patients with IPAH and healthy donors were obtained from the University of Giessen and Marburg Lung Center tissue bank. 9 These cells have been used in our previous study. 9 The IPAH pulmonary arterial fibroblasts exhibited greater proliferation capacity and increased FDG uptake. We extracted RNA by the Trizol method from PA adventitial fibroblasts and donor cells cultured in 6-well plates. Total RNA was transcribed with a High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems), followed by real-time polymerase chain reaction analysis of ENT1 and thymidine metabolism enzyme genes (TK1 and thymidine phosphorylase TP) using primers described in Table 2 .
Statistical Analysis
Data are presented as mean±SEM. Normal distribution was verified with the Kolmogorov-Smirnov test, and variance of homogeneity was tested by the Levene test. Differences between groups were assessed by either the Student t test or an appropriate ANOVA followed by the Bonferroni post hoc test for multigroup comparisons. Correlations between 18 FLT uptake (k 3 ) and clinical variables were determined by simple linear regression analyses. A P value <0.05 was considered statistically significant. All statistical analyses were performed using SPSS for Windows, version 20 (IBM Corp, Armonk, NY), and GraphPad Prism for Windows, version 5 (GraphPad Software, La Jolla, CA). 18 
RESULTS
Increased Rate of
FLT Phosphorylation k3 in IPAH Patient Lungs
The clinical characteristics of the patients with IPAH studied and details of the controls included in this study are summarized in Table 1 . We calculated the rates of 18 FLT transportation by 2T4k modeling 34 based on 60-minute PET imaging dynamic data acquisition. Compared with 18 FLT PET uptake in control subjects, 18 FLT phosphorylation, expressed as k 3 ( Figure 1A ), was increased significantly in IPAH patient lungs (0.086±0.034 versus 0.054±0.009; P<0.05). There was variation in k 3 within the IPAH group, such that some patients exhibited uptake >2-fold above the control group, whereas others were in the range of controls. Further analysis by 3D parametric mapping of computed per-voxel 18 FLT uptake from patients with IPAH demonstrated that focal areas of relatively high uptake were distributed unevenly throughout the lung parenchyma ( Figure 1B ; Figure IIIA in 18 FLT uptake from patient B showed a distinctive uneven regional pattern of 18 FLT signal compared with patient A.
We next looked at the relationship between lung 18 FLT uptake and cardiopulmonary hemodynamics in the IPAH group. There was no statistically significant correlation between lung 18 FLT uptake (phosphorylation rates k 3 ) and mean PA pressure (r=0.606, P=0.111) or pulmonary vascular resistance (r=0.0205, P=0.625; Figure 1C ). Interestingly, k 3 
Increased TK1, TP, and ENT1 Expression in IPAH Fibroblast
The vascular remodeling in PAH involves all cellular elements of the vessel wall, including fibroblasts. We have shown previously that pulmonary fibroblasts from patients with IPAH exhibit greater proliferation in vitro. 9 Here, we examined the expression of the thymidine metabolism enzymes TK1 and TP, as well as the thymidine transporter ENT1, in pulmonary fibroblasts isolated from 9 patients with IPAH and 12 donor lungs in culture. IPAH pulmonary fibroblasts demonstrated increased expression of ENT1, TP, and TK1 in comparison with control donor cells ( Figure 2B ).
Increased Lung 18 FLT Uptake in an MCT and SuHx PAH Model
To interpret the relationship between lung 18 FLT uptake and the underlying pulmonary vascular pathology, further studies were conducted in the MCT and SuHx PAH rat. Static images obtained from 60-minute dynamic PET acquisitions demonstrated significantly higher accumulation of 18 FLT in both MCT and SuHx rat lung ( Figure 3A) ; 18 FLT standardized uptake value in the 4-week MCT group was >50% greater than in Dynamic 60-minute PET data acquisition was used for kinetic modeling using a 2T4K compartmental model. There was a progressive increase in k 3 ( Figure 3B ) in 1-and 4-week MCT rat lungs, supported by direct tissue 18 FLT measurements ( Figure 3C ). Similar to the MCT rat model, compartmental modeling identified a significant increase in k 3 in SuHx rats ( Figure 3D ) compared with controls, and this was further confirmed by direct measurement of lung tissue 18 FLT uptake ( Figure 3E ). Histological examination of the MCT lung showed progressive vascular remodeling during 1 and 4 weeks post-MCT injection, as reported previously. 9 The remodeled vessels in both MCT and SuHx rat lung demonstrated Ki-67 expression, as well as prominent TK1 expression ( Figure 4A 
Attenuated Lung 18 FLT Uptake With IMA and DCA Treatment in the MCT Model
We investigated the response of 18 FLT PET measurements to treatments with proven antiproliferative efficacy in the MCT rat model. Treatment with DCA or IMA during weeks 2 to 4 post-MCT injection attenuated pulmonary vascular remodeling, as evidenced by significant reductions in the proportion of remodeled vessels with double elastic lamina ( Figure 5A ), Ki-67 score (5B), and RV hypertrophy (RV/LV+sep ratio, DCA: 0.48±0.03, IMA: 0.32±0.02; P<0.001 in comparison with placebo group: 0.61±0.02; Figure 5C ), consistent with previous data. 9 This was accompanied by a marked reduction in k 3 ( Figure 5D ) and further supported by the direct measurement of lung tissue 18 FLT uptake ( Figure 5E ).
Western blot analysis of lung homogenates demonstrated a significant increase in ENT1 and TK1 expression in the 4-week MCT rat lung, which was attenuated by both IMA and DCA treatment, respectively ( Figure 5F ).
DISCUSSION
This is the first study to explore the utility of dynamic 18 FLT PET imaging in patients with IPAH and rodent PAH models to report on pulmonary vascular pathology. We found that lung 18 FLT uptake was increased in patients with IPAH compared with control subjects and that there is heterogeneity in the lung 18 FLT signal in IPAH, both between patients and within the lungs of each patient. The MCT and SuHx rat models allowed us to investigate this signal in more depth. Increased lung 18 FLT uptake in MCT rats responded to drugs that reduce pulmonary vascular remodeling in animal models. Further in-depth kinetic 2T4k modeling of the lung 18 FLT signal showed an increased rate of 18 FLT phosphorylation, k 3 , together with prominent TK1 immunostaining in the remodeled pulmonary arteries of IPAH patient lungs and increased expression of thymidine metabolism genes in pulmonary arterial fibroblasts isolated from patients with IPAH. Our data support the contention that the lung 18 FLT PET signal reflects pulmonary vasculature cellular proliferation in PAH.
We have previously shown that 18 FDG uptake is increased in the lungs of patients with IPAH. 9 A limitation of 18 FDG is that it tracks general cellular metabolism, and we are challenged in distinguishing inflammation from proliferation by this approach. In the field of oncology, the 18 FLT ligand has been used for imaging tumor cell proliferation 26 and valued for improving the accuracy of antiproliferative target delineation. 18 FLT has been shown to correlate better than 18 FDG with cell proliferation markers in excised tumors and has potential to better differentiate growing tumors from inflammation. 40, 41 Importantly, background activity of 18 FLT is low in the thorax as shown in studies of lung cancer. [42] [43] [44] The potential clinical superiority of 18 FLT over 18 FDG-PET is evident in our data, where there is low noise in the 18 FLT signal at 95% threshold (voxels with R 2 >0.95); in comparison, 18 FDG lung uptake is more patchy at 60% threshold, indicating a relatively higher noise threshold ( Figure VII in the Data Supplement). In the current study, dynamic PET scanning data from patients with IPAH allowed us to perform an in-depth kinetic analysis of the rates of 18 FLT transportation in the lung by 2T4k modeling. 34 We found a significantly higher rate of 18 FLT phosphorylation in a proportion of IPAH patient lungs. The 18 FLT phosphorylation reaction is the TK1 ratelimiting step during S phase of the cell cycle, determining the uptake and retention of 18 FLT in tissue. TK1 overexpression has been described in various tumor tissues, including brain, breast, and lung tumors, and TK1 expression is correlated closely with Ki-67 expression, as well as 18 FLT uptake. [22] [23] [24] The measurement of intracellular levels of phosphorylated thymidine (as a surrogate of TK1 activation level) is regarded as an accurate method for estimating cellular growth. 16 Barthel et al, 45 using tumor implants with variant TK1 expression (denoted +/− and −/−) in mice, have shown that +/− tumors produced 48% more TK1 enzyme on average and also grew faster compared with −/− tumors. Importantly, uptake of 18 FLT was higher in +/− tumors compared with −/− tumors, while a converse pattern was found with 18 FDG imaging. These findings support the conclusion that imaging DNA synthesis is more accurate for the assessment of the proliferative potential of tumors, compared with radiotracer measurements of glucose consumption.
Direct correlation of 18 FLT uptake with vascular remodeling in the same human study subjects is not possible. We examined lung sections obtained from the Imperial College Pulmonary Hypertension biorepository and observed prominent TK1 immunostaining in remodeled pulmonary arteries in IPAH patient lungs. We also used pulmonary fibroblasts-an active contributor to vascular remodeling in IPAH-isolated from patients with IPAH to explore the biology in vitro. Consistent with increased lung uptake of 18 FLT PET and phosphorylation of 18 FLT in patients with IPAH, we observed significantly increased expression of thymidine metabolism enzymes, TK1 and TP, as well as the thymidine transporter, ENT1, in these hyperproliferative pulmonary vascular cells. These data are consistent with a lung 18 FLT signal that depicts the hyperproliferative vascular pathology documented in the pulmonary hypertensive lung.
There was considerable variation in the distribution of lung 18 FLT uptake within the small cohort of patients with IPAH. Some patients exhibited a >2-fold increase in k 3 above the control group, whereas others were in the range of controls. This is not sur- prising because vascular proliferation is unlikely to be constant throughout the course of the disease. Little is known about the natural history of the vascular pathology of IPAH; for example, it could be episodic with periods of vascular proliferation interspersed with periods of relative quiescence, or vascular remodeling could be an early event with little cellular activity during the later stages of the disease. A cross-sectional study of patients with IPAH would be expected to reflect this variation. Furthermore, we analyzed data by 3D parametric mapping of computed per-voxel (2 mm 2 per voxel) 18 FLT uptake. There was an uneven pattern in the 18 FLT signal distribution within the lungs of patients with severe disease, which may reflect the patchy distribution of the vascular pathology within the lung seen on histological examination. 4, 6 This temporal and spacial variability in pulmonary vascular remodeling in the lungs of patients with PAH is likely to explain the absence of an association between overall lung 18 FLT phosphorylation and mean PA pressure or pulmonary vascular resistance in this small cohort of patients with IPAH. The lack of association does not diminish the utility of 18 FLT PET as a clinical tool but offers new possibilities for drug development and personalized medicine. With the focus now on developing drugs that tackle pulmonary vascular remodeling (as opposed to vasoconstriction) and many potential drug targets, it is important to have an efficient method for filtering out agents that have therapeutic potential by this mechanism of action from those that are not likely to work. 18 FLT PET could offer a bridging biomarker-a method for evaluating the action of a drug in an animal model that can also be used to provide mechanistic data in patients and provide early dose-response information before any change in vascular resistance.
To that end, the changes in 18 FLT PET signal in response to treatment in the experimental MCT and SuHx models are significant. The remodeled vessels in the MCT and SuHx rat lungs demonstrated increased Ki-67 expression, as well as prominent TK1 expression. k 3 was also increased in proportion to the proliferation Ki-67 score. An increase in 18 FLT signal was seen at 1 week, before significant changes in hemodynamic measurements are observed in this model. 39 Treatment with DCA and IMA attenuated pulmonary hypertension and vascular remodeling and reduced the diseasedriven increase in lung TK1 and ENT1 expression. 18 FLT PET lung uptake was also reduced in the treated animal groups, consistent with decreased peripheral vascular muscularization.
These data support the concept that 18 FLT PET may be a useful tool to evaluate novel antiproliferative therapies in patients with PAH. It can be a critical part of clinical trials where the objective is to gain evidence that a new treatment is targeting the proliferative component that drives the structural changes in the pulmonary vas- culature, and further investigation is urgently needed. We suggest that given the variability in uptake between patients, it might also be a useful tool for identifying patients who might benefit the most from antiproliferative therapy and so support precision medicine. 18 FLT uptake in MCT rats. %ID/g indicates percentage of injected dose per gram of tissue. F, Summary data and representative Western blot for TK1 (thymidine kinase 1) and ENT1 (equilibrative nucleoside transporter 1) expression in whole-lung homogenate. Both TK1 and ENT1 expressions, normalized to GAPDH, were increased in the MCT rat and attenuated by DCA and IMA treatment. Data are expressed as mean±SEM; n≥5 per group. *P<0.05, **P<0.01, ***P<0.001.
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